Genetic Technologies is a molecular diagnostics company that provides predictive testing and assessment tools to help physicians manage women's health. Co.'s key product, BREVAGenplus, was a clinically validated risk assessment test for non-hereditary breast cancer. Co. has launched the first generation BREVAGen test across the U.S. via its U.S. subsidiary Phenogen Sciences Inc. Co. has developed two new cancer risk assessment tests branded as GeneType for Colorectal Cancer and GeneType for Breast Cancer. Co. also develops other risk assessment tests across a range of diseases, including cardiovascular disease, type 2 diabetes, prostate cancer and melanoma. The GENE YTD return is shown above.
The YTD Return on the GENE YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether GENE YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the GENE YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|